ClinicalTrials.gg
CompletedNCT01561937Updated Nov 25, 2016

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

A Phase 1 interventional study of warfarin and eptacog alfa (activated) in Haemostasis and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-25.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with warfarin to reach a targeted INR (International Normalization Ratio).

02

Conditions studied

  • Haemostasis
  • Healthy
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • below or equal to 1.2

Exclusion criteria

Exclusion Criteria:

  • The receipt of any drug within 1 month prior to this trial
  • Use of anticoagulation therapy-defined as vitamin K antagonists, antagonists, heparin (or low molecular weight heparin), aspirin or NSAIDs (Non-Steroidal Anti-Inflammatory Drug) within 14 days prior to trial
  • African-American race
  • Weight above 160 kg
  • Supplemental Vitamin K use
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Pre-warfarin treatment (trial part A)

    Drug: warfarin

  • Experimental
    Post-warfarin treatment (trial part B)

    Drug: eptacog alfa (activated) · Drug: placebo

Interventions

  • After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed

  • If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration

    Also known as: activated recombinant human factor VII

  • Drugplacebo

    If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration

06

What researchers measure

Primary outcomes

  1. Bleeding duration measured in minutes after biopsies in trial part A

    Time frame: From onset of bleeding till the end of the bleeding

  2. Bleeding duration measured in minutes after biopsy B1 in trial part B

    Time frame: From onset of bleeding till the end of the bleeding

Secondary outcomes

  1. Blood volume reported in millilitres after biopsies in trial part A

    Time frame: From onset of bleeding till the end of the bleeding

  2. Blood volume reported in millilitres after biopsy B1 in trial part B

    Time frame: From onset of bleeding till the end of the bleeding

  3. Adverse events, including thrombotic events

    Time frame: From day 0 to days 14-28

  4. Change in coagulation-related parameters after biopsy B1

    Time frame: From baseline to 3 hours after B1

  5. Change in coagulation-related parameters after biopsy B2

    Time frame: From baseline to 3 hours after B2

  6. Change in coagulation-related parameters after biopsy B3

    Time frame: From baseline to 3 hours after B3

  7. Clot dynamics: R in minutes (trial part B)

    Time frame: Time to onset of clot formation

  8. Clot dynamics: K in minutes (trial part B)

    Time frame: Time to achieve 20mm clot strength

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Overland Park, Kansas 66211, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2012
First posted
Mar 23, 2012
Start
Jan 2007
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Last update
Nov 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01561937
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 23, 2012
Start date
Jan 2007
Primary completion
Jul 2008
Completion
Jul 2008
Last update
Nov 25, 2016

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Warfarin · Recombinant FVIIa

Start the discussion